267 related articles for article (PubMed ID: 17168689)
1. In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor.
Zhang D; Hanson R; Roongta V; Dischino DD; Gao Q; Sloan CP; Polson C; Keavy D; Zheng M; Mitroka J; Yeola S
Curr Drug Metab; 2006 Dec; 7(8):883-96. PubMed ID: 17168689
[TBL] [Abstract][Full Text] [Related]
2. In vitro drug metabolism of green tea catechins in human, monkey, dog, rat and mouse hepatocytes.
Chen WW; Qin GY; Zhang T; Feng WY
Drug Metab Lett; 2012 Jun; 6(2):73-93. PubMed ID: 22594564
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo metabolism of a selective δ-opioid receptor.
Guo J; Gu C; Zhou D; Elmore CS; Bui KH; Grimm SW
Drug Metab Dispos; 2011 Oct; 39(10):1883-94. PubMed ID: 21752944
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism.
Wu WN; McKown LA; Reitz AB
Eur J Drug Metab Pharmacokinet; 2006; 31(4):277-83. PubMed ID: 17315539
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.
Dean BJ; Chang S; Silva Elipe MV; Xia YQ; Braun M; Soli E; Zhao Y; Franklin RB; Karanam B
Drug Metab Dispos; 2007 Feb; 35(2):283-92. PubMed ID: 17132765
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
Christopher LJ; Cui D; Li W; Barros A; Arora VK; Zhang H; Wang L; Zhang D; Manning JA; He K; Fletcher AM; Ogan M; Lago M; Bonacorsi SJ; Humphreys WG; Iyer RA
Drug Metab Dispos; 2008 Jul; 36(7):1341-56. PubMed ID: 18420785
[TBL] [Abstract][Full Text] [Related]
8. In vitro studies on the oxidative metabolism of 20(s)-ginsenoside Rh2 in human, monkey, dog, rat, and mouse liver microsomes, and human liver s9.
Li L; Chen X; Zhou J; Zhong D
Drug Metab Dispos; 2012 Oct; 40(10):2041-53. PubMed ID: 22829543
[TBL] [Abstract][Full Text] [Related]
9. Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction.
Zheng M; Wang J; Lubinski J; Flint OP; Krishna R; Yao M; Pursley JM; Thakur A; Boulton DW; Santone KS; Barten DM; Anderson JJ; Felsenstein KM; Hansel SB
Xenobiotica; 2009 Jul; 39(7):544-55. PubMed ID: 19480557
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of a thiazole benzenesulfonamide derivative, a potent and elective agonist of the human beta3-adrenergic receptor, in rats: identification of a novel isethionic acid conjugate.
Tang W; Stearns RA; Miller RR; Ngui JS; Mathvink RJ; Weber AE; Kwei GY; Strauss JR; Keohane CA; Doss GA; Chiu SH; Baillie TA
Drug Metab Dispos; 2002 Jul; 30(7):778-87. PubMed ID: 12065436
[TBL] [Abstract][Full Text] [Related]
11. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.
Xu L; Woodward C; Khan S; Prakash C
Drug Metab Dispos; 2012 Apr; 40(4):680-93. PubMed ID: 22217465
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of l-corydalmine, a potent analgesic drug, in human, cynomolgus monkey, beagle dog, rat and mouse liver microsomes.
Tang X; Di X; Zhong Z; Xie Q; Chen Y; Wang F; Ling Z; Xu P; Zhao K; Wang Z; Liu L; Liu X
J Pharm Biomed Anal; 2016 Sep; 128():98-105. PubMed ID: 27239758
[TBL] [Abstract][Full Text] [Related]
14. Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR.
Mutlib AE; Shockcor J; Chen SY; Espina RJ; Pinto DJ; Orwat MJ; Prakash SR; Gan LS
Chem Res Toxicol; 2002 Jan; 15(1):48-62. PubMed ID: 11800597
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.
Cheng Y; Wang L; Iacono L; Zhang D; Chen W; Gong J; Humphreys WG; Gan J
Br J Clin Pharmacol; 2018 Jan; 84(1):130-141. PubMed ID: 28850715
[TBL] [Abstract][Full Text] [Related]
17. Identification of in vivo and in vitro metabolites of 4,5-dimethoxycanthin-6-one by HPLC-Q-TOF-MS/MS.
Miao X; Wang J; Chen L; Peng Z; Chen Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1020():78-84. PubMed ID: 27030894
[TBL] [Abstract][Full Text] [Related]
18. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards.
Zhang D; Zhang H; Aranibar N; Hanson R; Huang Y; Cheng PT; Wu S; Bonacorsi S; Zhu M; Swaminathan A; Humphreys WG
Drug Metab Dispos; 2006 Feb; 34(2):267-80. PubMed ID: 16280454
[TBL] [Abstract][Full Text] [Related]
19. Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide.
Kochansky CJ; Xia YQ; Wang S; Cato B; Creighton M; Vincent SH; Franklin RB; Reed JR
Drug Metab Dispos; 2005 Dec; 33(12):1894-904. PubMed ID: 16183782
[TBL] [Abstract][Full Text] [Related]
20. Species difference in glucuronidation formation kinetics with a selective mTOR inhibitor.
Berry LM; Liu J; Colletti A; Krolikowski P; Zhao Z; Teffera Y
Drug Metab Dispos; 2014 Apr; 42(4):707-17. PubMed ID: 24423753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
